May 2023 Global Innovative Drug Report

This May 2023 Global Innovative Drug Report offers a comprehensive overview of the latest advancements in the pharmaceutical industry and an analysis of each selected drug. Within the report, we delve into various aspects of each drug, including its snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other crucial factors.

Download it now to learn about:

The first approved drugs in May
New drug analysis
Global drugs under expedited review pathway in May
Analysis of selected ERP drugs

May 2023 Global Innovative Drug Report Overview

1.) Drugs Approved in May

In May 2023, a total of 18 drugs received global approval, representing a diverse range of therapeutic categories. These include:

4 Small molecule drugs (SMD)
4 Monoclonal antibodies (mAb)
2 Prophylactic vaccines
2 Allergen extracts
1 Blood component
1 Gene therapy
1 Bispecific antibody
1 Enzyme
1 Fusion protein
1 Synthetic peptide

May 2023 Global Approved Drugs, Synapse

2.) Comprehensive Analysis of Newly Introduced Medications

This report also offers a comprehensive analysis of five recently approved drugs, providing valuable insights into their profiles and impact. Let’s delve into the in-depth analysis of Benegrastim, one of the featured drugs, which encompasses the following comprehensive details:

Benegrastim Snapshot & R&D Status, Patsnap Synapse

Benegrastim Active Patent & Analysis, Patsnap Synapse

Benegrastim Analysis Continued, Patsnap Synapse

3.) Global Drugs Under Expedited Review Pathway in May

In May 2023, there were 57 drugs worldwide undergoing Expedited Review pathways. These included:

32 Orphan Drug designations
12 Fast Track designations
5 Priority reviews
4 Breakthrough Therapy designations
2 Regenerative Medicine Advanced Therapy designations
1 Innovative Licensing and Access Pathway (ILAP)
1 Accelerated Approval

These designations and pathways aim to accelerate the evaluation and approval process, ensuring timely access to innovative treatments for patients in need.

May 2023 Global Drugs Subject to Expedited Review, Synapse

4.) Analysis of Selected ERP Drugs

Within this report, we selected five drugs under Expedited Review pathways for detailed analysis. Now, let’s explore the report content focused on Spesolimab, which provides an in-depth examination of the following key details:

Spesolimab Snapshot & R&D Status, Patsnap Synapse

Spesolimab Active Patents & Analysis, Patsnap Synapse

Spesolimab Analysis Continued, Patsnap Synapse

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Copyright Statement: This report is the sole property of PatSnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from PatSnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. PatSnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact phs@patsnap.com.